Willem H. van Harten

prof.dr.

Other Research Staff, Health Technology & Services Research

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Willem H. van Harten is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

75 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

Securing sustainable price levels of innovative anticancer drugs: How to move forward?
Franzen, N., Retèl, V. & van Harten, W., 1 Mar 2021, In : Journal of Cancer Policy. 27, 100266.
Research output: Contribution to journal › Article › Academic › peer-review
Selecting Image-Guided Surgical Technologies in Oncology: A Surgeon's Perspective
Lindenberg, M., Retèl, V., van Til, J., Kuhlmann, K., Ruers, T. & van Harten, W., Jan 2021, In : Journal of Surgical Research. 257, p. 333-343 11 p.
Research output: Contribution to journal › Article › Academic › peer-review
Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
3 Jan 2021, In : Breast cancer research and treatment.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
100 European core quality standards for cancer care and research centres
Oberst, S., van Harten, W., Sæter, G., de Paoli, P., Nagy, P., Burrion, J. B., Lovey, J. & Philip, T., 1 Aug 2020, In : The Lancet Oncology. 21, 8, p. 1009-1011 3 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
Retèl, V. P., Byng, D., Linn, S. C., Jóźwiak, K., Koffijberg, H., Rutgers, E. J., Cardoso, F., Piccart, M. J., Poncet, C., van't Veer, L. J. & van Harten, W. H., Sep 2020, In : European journal of cancer. 137, p. 193-203 11 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File
1 Citation (Scopus)

21 Downloads (Pure)

1 Oral presentation

Alliantie Regionale Topzorg
Willem H. van Harten (Speaker)
4 Mar 2015
Activity: Talk or presentation › Oral presentation

Securing sustainable price levels of innovative anticancer drugs: How to move forward?

Selecting Image-Guided Surgical Technologies in Oncology: A Surgeon's Perspective

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?

100 European core quality standards for cancer care and research centres

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

Alliantie Regionale Topzorg